EP1746993A4 - Compositions a base de metformine a liberation regulee - Google Patents

Compositions a base de metformine a liberation regulee

Info

Publication number
EP1746993A4
EP1746993A4 EP05742346A EP05742346A EP1746993A4 EP 1746993 A4 EP1746993 A4 EP 1746993A4 EP 05742346 A EP05742346 A EP 05742346A EP 05742346 A EP05742346 A EP 05742346A EP 1746993 A4 EP1746993 A4 EP 1746993A4
Authority
EP
European Patent Office
Prior art keywords
controlled release
release metformin
metformin compositions
compositions
controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05742346A
Other languages
German (de)
English (en)
Other versions
EP1746993A1 (fr
Inventor
Xiu-Xiu Cheng
Edward I Cullen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andrx Laboratories LLC
Original Assignee
Andrx Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Laboratories LLC filed Critical Andrx Laboratories LLC
Publication of EP1746993A1 publication Critical patent/EP1746993A1/fr
Publication of EP1746993A4 publication Critical patent/EP1746993A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP05742346A 2004-04-29 2005-04-29 Compositions a base de metformine a liberation regulee Withdrawn EP1746993A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56649104P 2004-04-29 2004-04-29
PCT/US2005/014826 WO2005107750A1 (fr) 2004-04-29 2005-04-29 Compositions a base de metformine a liberation regulee

Publications (2)

Publication Number Publication Date
EP1746993A1 EP1746993A1 (fr) 2007-01-31
EP1746993A4 true EP1746993A4 (fr) 2007-08-29

Family

ID=35320027

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05742346A Withdrawn EP1746993A4 (fr) 2004-04-29 2005-04-29 Compositions a base de metformine a liberation regulee

Country Status (4)

Country Link
EP (1) EP1746993A4 (fr)
JP (1) JP2007535557A (fr)
CA (1) CA2564750A1 (fr)
WO (1) WO2005107750A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036100A1 (fr) * 2000-11-03 2002-05-10 Andrx Corporation Compositions de metformine a liberation controlee
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US6653332B2 (en) * 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036100A1 (fr) * 2000-11-03 2002-05-10 Andrx Corporation Compositions de metformine a liberation controlee
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2005107750A1 *

Also Published As

Publication number Publication date
CA2564750A1 (fr) 2005-11-17
WO2005107750A1 (fr) 2005-11-17
JP2007535557A (ja) 2007-12-06
EP1746993A1 (fr) 2007-01-31

Similar Documents

Publication Publication Date Title
GB0406819D0 (en) Controlled release compositions
EP1656115A4 (fr) Compositions a liberation controlee
EP1718714A4 (fr) Compositions contenant un traceur
GB0409375D0 (en) Phytoactive composition
ZA200904425B (en) Nemathical compositions
EP1726304A4 (fr) Composition contenant de la solifenacine
EP1607088A4 (fr) Composition lib ration contr l e
PL1827105T3 (pl) Kompozycja herbicydowa
GB0405406D0 (en) Anti-vaginitis compositions
GB0425795D0 (en) Composition
GB0416861D0 (en) Composition
GB0410038D0 (en) Composition
IL177328A0 (en) Controlled release formulations
GB0414803D0 (en) Composition
GB0415981D0 (en) Composition
GB0417357D0 (en) Composition
ZA200701197B (en) Compositions
GB0410140D0 (en) Compositions
EP1746993A4 (fr) Compositions a base de metformine a liberation regulee
GB0420627D0 (en) Monoglyceride-containing compositions
GB0417388D0 (en) Composition
GB0426717D0 (en) Herbicidal composition
GB0419489D0 (en) Weathered-effect composition
GB0409598D0 (en) Composition
GB0322044D0 (en) Controlled release compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061026

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20070727

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/36 20060101ALI20070723BHEP

Ipc: A61P 5/48 20060101ALI20070723BHEP

Ipc: A61K 31/155 20060101AFI20070723BHEP

17Q First examination report despatched

Effective date: 20101221

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110503